Cargando…
Prognostic relevance of LGALS3BP in human colorectal carcinoma
BACKGROUND: A previous report has shown that LGALS3BP (also known as 90K or Mac-2 BP) has antitumor activity in colorectal cancer (CRC) via suppression of Wnt signalling with a novel mechanism of ISGylation-dependent ubiquitination of β-catenin. The role of LGALS3BP in CRC prognosis was investigated...
Autores principales: | Piccolo, Enza, Tinari, Nicola, D’Addario, Domenica, Rossi, Cosmo, Iacobelli, Valentina, La Sorda, Rossana, Lattanzio, Rossano, D’Egidio, Maurizia, Di Risio, Annalisa, Piantelli, Mauro, Natali, Pier Giorgio, Iacobelli, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518516/ https://www.ncbi.nlm.nih.gov/pubmed/26219351 http://dx.doi.org/10.1186/s12967-015-0606-x |
Ejemplares similares
-
Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma
por: Capone, Emily, et al.
Publicado: (2020) -
Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2013) -
Extracellular LGALS3BP: a potential disease marker and actionable target for antibody–drug conjugate therapy in glioblastoma
por: Dufrusine, Beatrice, et al.
Publicado: (2023) -
Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer
por: Lattanzio, R, et al.
Publicado: (2014) -
EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors
por: Capone, Emily, et al.
Publicado: (2021)